IBT
TVTX icon

International Biotechnology Trust’s Travere Therapeutics TVTX Stock Holding History

International Biotechnology Trust’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-441,019
Closed -$6.77M – 69
2023
Q2 		$6.77M Buy
441,019
+300,000
+213% +$5.46M 2.06% 17
2023
Q1 		$3.17M Sell
141,019
-238,000
-63% -$5.06M 0.88% 33
2022
Q4 		$7.96M Buy
379,019
+193,000
+104% +$4.09M 2.46% 16
2022
Q3 		$4.58M Buy
186,019
+176,804
+1,919% +$4.57M 1.47% 23
2022
Q2 		$380K Sell
9,215
-370,785
-98% -$9.32M 3.96% 7
2022
Q1 		$1.55M Hold
380,000
– – 0.35% 47
2021
Q4 		$11.8M Hold
380,000
– – 2.63% 12
2021
Q3 		$9.21M Buy
380,000
+360,000
+1,800% +$6.61M 2.22% 16
2021
Q2 		$292K Hold
20,000
– – 0.08% 64
2021
Q1 		$499K Hold
20,000
– – 0.13% 53
2020
Q4 		$545K Buy
+20,000
New +$467K 0.15% 48
2019
Q3 		– Sell
-18,000
Closed -$362K – 63
2019
Q2 		$362K Sell
18,000
-190,000
-91% -$3.75M 0.13% 63
2019
Q1 		$4.7M Buy
+208,000
New +$4.6M 1.74% 22

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

International Biotechnology Trust's TVTX Position: Q3 2023 in Review

International Biotechnology Trust sold out of Travere Therapeutics (TVTX) in Q3 2023, closing a stake of 441,019 shares — an estimated $6.77M sold.

International Biotechnology Trust first reported a position in TVTX in Q1 2019 and held it in 13 quarters. The position peaked at $11.8M in Q4 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q3 2023.

  • International Biotechnology Trust reported no remaining Travere Therapeutics position as of Q3 2023 after selling out during the quarter.
  • International Biotechnology Trust sold 441,019 Travere Therapeutics shares in Q3 2023, an estimated $6.77M.
  • International Biotechnology Trust first reported a position in Travere Therapeutics in Q1 2019 and held it in 13 quarters.
  • International Biotechnology Trust's Travere Therapeutics position peaked at $11.8M in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.